Navigation Links
PDL BioPharma Announces Conversion Rate Adjustments for its Convertible Notes
Date:6/6/2011

INCLINE VILLAGE, Nev., June 6, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced an adjustment to the conversion rate for:

  • The 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes), effective June 9, 2011;
  • The 2.875% Convertible Senior Notes due February 15, 2015 (the 2015 Notes), effective June 9, 2011; and
  • The 3.75% Convertible Senior Notes due May 1, 2015 (the May 2015 Notes), effective June 6, 2011,

in connection with the regular dividend to be paid on June 15, 2011, to all stockholders who own shares of PDL on June 8, 2011, the record date.

The conversion rate for the 2012 Notes and the 2015 Notes, as adjusted, is 147.887 shares of common stock per $1,000 principal amount or $6.76 per share. The conversion rate for the 2012 Notes and the 2015 Notes was previously 144.474 shares of common stock per $1,000 principal amount of the 2012 Notes and the 2015 Notes. In connection with a cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the five consecutive trading days immediately preceding the ex-dividend date of June 6, 2011, for the cash dividend, and the denominator of which is the difference of such average closing price less the dividend amount.

The conversion rate for the May 2015 Notes, as adjusted, is 129.2740 shares of common stock per $1,000 principal amount or $7.74 per share. The conversion rate for the May 2015 Notes was previously 126.2985 shares of common stock per $1,000 principal amount of the May 2015 Notes. In connection with a cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the ten consecutive trading days immediately preceding the ex-dividend date of June 6, 2011, for the cash dividend, and the denominator of which is the difference of such average closing price less the dividend amount.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

The foregoing statements regarding PDL's intentions with respect to the cash dividend payment described above are forward-looking statements under the Private Securities Litigation Reform Act of 1995 and actual results could vary materially from the statements made. PDL's ability to pay the dividend described above is subject to various risks, many of which are outside its control, including prevailing conditions in the capital markets, the continued strength of its royalty assets and other risks and uncertainties as detailed from time to time in the reports filed by PDL with the Securities and Exchange Commission.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PDL BioPharma, Inc. Prices Offering of $135.0 Million of Convertible Senior Notes Due 2015
2. Vista Partners Initiates Coverage on Helix BioPharma Corporation; Target Price $6.20
3. Plato BioPharma Presenting Poster at the American Thoracic Society Conference
4. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
5. PDL BioPharma to Present at Upcoming Conferences
6. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
7. New Biopharmaceutical Company to Accelerate Delivery of Vaccines and Protein Therapeutics
8. PDL BioPharma to Announce First Quarter 2011 Financial Results on April 27, 2011
9. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
10. PDL BioPharma to Hold Annual Meeting of Stockholders on June 22, 2011
11. Plato BioPharma, Inc. Sponsors Novel Disease Model Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, ... Canada , today announced two new real-world data analyses ... 65 th Annual Pacific Coast Reproductive Society (PCRS) Meeting ... 24 th .   The results being presented are ... 2009 to December 2015 containing data from 15 fertility clinics ...
(Date:3/22/2017)... 22, 2017 NetworkNewsWire Editorial Coverage  ... Deciphering marijuana ... statements by White House officials. Federal laws are at odds ... medical and/or recreational use, and businesses like SinglePoint, Inc. (OTC: ... CRBP), Medical Marijuana, Inc. (OTC: MJNA), Cannabis Science, Inc. (OTC: ...
(Date:3/22/2017)... 2017 Biosensors International Group, Ltd. ("Biosensors" or the ... the enrollment of the first American patient in LEADERS FREE II, its ... will include sites in the United States , ... Italy , and the United Kingdom . ... The BioFreedom drug-coated stent (DCS) ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... 22, 2017 , ... In recognition of Colon Cancer Awareness ... on cancer patients, cancer centers and advocacy groups, and MJH Studios™, a leading ... “No Ifs, Ands, or Butts,” that focuses on Colorectal Cancer detection, prevention and ...
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson and ... patients in need of skilled pediatric dentistry in Rock Hill, SC, without ... patients routine treatments, including cavities, sealants and fluoride applications, in a comfortable and fun ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... throughout north Jersey and the New York metropolitan region, is embarking on a ... for homeless families. , At present, more than two and a half million ...
(Date:3/22/2017)... ... March 22, 2017 , ... Schneider Insurance and Financial, a southern Montana ... the Yellowstone Valley region, is launching a charity event aimed at raising local support ... all of Montana State, and is home to a broad variety of animals from ...
(Date:3/22/2017)... ... ... The Senior Citizens League (TSCL) is calling on Congressional leadership to lift ... including the debt held by the Social Security Trust Fund. “Congressional inaction on ... House and Senate budget leaders. “In prior debates to lift the debt ceiling, ...
Breaking Medicine News(10 mins):